COVERAGE / LLY / Healthcare

ELI LILLY & Co

Pharmaceutical Preparations

COVERAGE STATUSACTIVE

DATA THROUGH2025-12-31

RESEARCH REPORTS2

SELECTED FILINGS1

Fundamental matrix

Latest / 2025-12-31 · Prior / 2024-12-31 · USD · Annual periods

Revenue

$65.18bn

Prior / $45.04bn

Change / +44.70%

SOURCE / 2026-02-12

Operating income

Not available

Prior / Not available

Change / Unavailable

SOURCE / Not available

Net income

$20.64bn

Prior / $10.59bn

Change / +94.90%

SOURCE / 2026-02-12

Diluted EPS

$22.95

Prior / $11.71

Change / +95.99%

SOURCE / 2026-02-12

Free cash flow

Not available

Prior / Not available

Change / Unavailable

SOURCE / 2026-02-12

Gross margin

Not available

Prior / Not available

Change / Unavailable

SOURCE / Not available

Operating margin

Not available

Prior / Not available

Change / Unavailable

SOURCE / Not available

Return on avg. equity

101.16%

Prior / 84.57%

Change / +16.59 pp

SOURCE / 2026-02-12

Debt / equity

Not available

Prior / Not available

Change / Unavailable

SOURCE / Not available

ROE uses net income divided by average opening/closing equity. FCF = operating cash flow − selected capital expenditure. Debt/equity is unavailable because a verified interest-bearing-debt series is absent; total liabilities are not substituted for debt.

Inspect source tags, dates and accession numbers

{
  "revenue": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 65179000000,
    "accn": "0000059478-26-000013",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-12",
    "frame": "CY2025",
    "tag": "us-gaap:Revenues",
    "unit": "USD"
  },
  "netIncome": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 20640000000,
    "accn": "0000059478-26-000013",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-12",
    "frame": "CY2025",
    "tag": "us-gaap:NetIncomeLoss",
    "unit": "USD"
  },
  "eps": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 22.95,
    "accn": "0000059478-26-000013",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-12",
    "frame": "CY2025",
    "tag": "us-gaap:EarningsPerShareDiluted",
    "unit": "USD/shares"
  },
  "operatingCashFlow": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 16813000000,
    "accn": "0000059478-26-000013",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-12",
    "frame": "CY2025",
    "tag": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
    "unit": "USD"
  },
  "totalAssets": {
    "end": "2025-12-31",
    "val": 112476000000,
    "accn": "0000059478-26-000013",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-12",
    "tag": "us-gaap:Assets",
    "unit": "USD"
  },
  "shareholdersEquity": {
    "end": "2025-12-31",
    "val": 26535000000,
    "accn": "0000059478-26-000013",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-12",
    "tag": "us-gaap:StockholdersEquity",
    "unit": "USD"
  },
  "currentAssets": {
    "end": "2025-12-31",
    "val": 55629000000,
    "accn": "0000059478-26-000013",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-12",
    "tag": "us-gaap:AssetsCurrent",
    "unit": "USD"
  },
  "currentLiabilities": {
    "end": "2025-12-31",
    "val": 35228000000,
    "accn": "0000059478-26-000013",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-12",
    "tag": "us-gaap:LiabilitiesCurrent",
    "unit": "USD"
  }
}

Financial trend system

Annual financial trends are summarized in the accessible table below.

Annual figures / accessible table

Period end	Revenue	Net income	Free cash flow	EPS
2025-12-31	$65.18bn	$20.64bn	Not available	$22.95
2024-12-31	$45.04bn	$10.59bn	Not available	$11.71
2023-12-31	$34.12bn	$5.24bn	Not available	$5.80
2022-12-31	$28.54bn	$6.24bn	Not available	$6.90

Valuation context

Historical snapshot / 2026-09-17. Annual accounting period / 2025-12-31. Not current, TTM or forward valuation.

Dated ratios / eligible same-method sector sample
Measure	Snapshot value	Historical median	Sector median	Peer count
P/E	50.22x	Unavailable	27.08x	10
P/S	16.64x	Unavailable	6.63x	10
P/B	40.88x	Unavailable	7.31x	8
EV / EBITDA	Unavailable	Unavailable	Unavailable	0
FCF yield	Unavailable	Unavailable	3.88%	8

Annual denominators, not TTM or forward. Capitalization-based measures use estimated market capitalization from the dated quote snapshot. ADR/share-basis uncertainty is excluded. No comparable historical-multiple series or EV/EBITDA is available. Sector samples are equal-weight medians of this publication’s eligible covered companies; fiscal periods differ. No fair value or price target is implied.

Source: Yahoo Finance completed daily-bar snapshot; not live; market cap estimated using SEC shares at 2026-08-03 DAILY-BAR SOURCE ↗

Retained price snapshot and capitalization estimate

{
  "currentPrice": 1152.4399,
  "tradingDate": "2026-09-17",
  "marketCap": 1084857441852.89,
  "source": "Yahoo Finance completed daily-bar snapshot; not live; market cap estimated using SEC shares at 2026-08-03"
}

Company & operating context

ELI LILLY & Co is an SEC-reporting issuer listed on NYSE under LLY. Its SEC industry description is Pharmaceutical Preparations. This profile organizes annual financial disclosures for research; sector labels are editorial groupings, not GICS classifications.

Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.

Segment-level revenue is not included in this standardized dataset. Consult the business and segment notes in the linked annual filing for the issuer’s actual reporting segments.

Filing timeline

10-KFILED / 2026-02-12PERIOD / 2025-12-31

LLY filed this 10-K on 2026-02-12 for the reported period 2025-12-31. Reading focus: Product concentration, research investment, utilization, reimbursement and cash generation. This is a metadata-based reading guide; it does not assert that a particular event or risk change occurred in the document.

ORIGINAL SEC DISCLOSURE ↗

Research archive

HR-0087LLYEarnings Review

LLY: the annual earnings and cash-flow comparison ↗

ELI LILLY & Co

Research abstract

A two-period review of LLY revenue, profitability and cash conversion; reported revenue growth was 44.70%.

DATA THROUGH2025-12-312 MIN READPUBLISHED 2026-09-26

HR-0088LLYCompany Research

LLY: reading the FY2025 financial structure ↗

ELI LILLY & Co

Research abstract

Annual revenue of USD 65.179 billion and net income of USD 20.640 billion for the period ended 2025-12-31.

DATA THROUGH2025-12-312 MIN READPUBLISHED 2026-09-26

Sector context & risk factors

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration.

Product concentration, research investment, utilization, reimbursement and cash generation.

HEALTHCARE SYSTEM ↗

Sources & dates

SEC annual filing · 2025-12-31 ↗Source date 2026-02-12
SEC annual filing · 2024-12-31 ↗Source date 2026-02-12
SEC annual filing · 2023-12-31 ↗Source date 2026-02-12
SEC annual filing · 2022-12-31 ↗Source date 2025-02-19
SEC issuer record ↗Source date 2026-09-18